SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing intense market volatility and significant analyst downgrades following a weak bookings guidance reset and the disruptive impact of its new age verification rollout. The community remains deeply polarized, with many investors debating whether the current selloff offers a buying opportunity in a sticky platform or if persistent safety concerns and slowing growth justify further downside.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending following the announcement of a $30 million private placement and a new licensing deal for an anti-IgE asset, which has triggered intense speculation regarding its potential for a short squeeze among retail traders. While some investors are highlighting the company's clinical pipeline and low float as catalysts for a major rally, others remain skeptical, pointing to the effective offering price and potential dilution risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors digest a massive earnings beat, with the community actively debating whether the company's strong monetization and user growth can spark a sustained rally or if the stock will face typical post-earnings volatility. While bulls point to improved profitability and long-term data licensing potential as catalysts for a squeeze, bears remain skeptical, citing concerns over user engagement quality and historical patterns of post-report pullbacks.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing significant bullish momentum driven by the upcoming presentation of its pancreatic cancer trial data at Digestive Disease Week, which has investors anticipating a major clinical breakthrough. Community sentiment remains overwhelmingly optimistic, with retail traders aggressively accumulating shares and discussing potential catalystsincluding trial expansions and upcoming gala eventsas the stock continues to trend on high volume.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is seeing significant market activity following a record-breaking fiscal quarter that featured double-digit revenue growth and a new $100 billion share buyback authorization. Investors are actively debating the leadership transition to incoming CEO John Ternus and the company's long-term growth outlook, with community discussion centered on supply chain constraints, margin pressure from memory costs, and anticipation for upcoming AI product reveals.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and a parabolic rally driven by a extremely low tradeable float, which has triggered an aggressive short squeeze as borrow fees have surged toward 1000%. The community is intensely debating the sustainability of this run, with many bullish traders focused on momentum and the potential for forced short covering, while skeptics point to the company's history of reverse splits and warn of an inevitable correction.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing extreme volatility following a massive quarterly earnings beat that saw revenue triple and guidance raised, with the community divided between bulls viewing the pullback as a gift and bears warning of a potential bubble after a year of historic gains. Investors are closely monitoring the $6 billion share buyback announcement and the company's aggressive expansion into AI data center infrastructure as key indicators for whether the stock can maintain its upward trajectory.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is facing intense downward pressure and community criticism following the announcement of an $80 million capital raise through a common stock and pre-funded warrant offering. Investors are actively debating the company's management execution and the potential for further dilution, as the stock struggles to find footing amidst recurring concerns over the firm's long-term business model.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is attracting significant investor attention following a powerful earnings report where it beat revenue expectations and raised guidance, highlighting the success of its AI-driven Athena platform. The community is actively debating the stock's potential for a short squeeze and its long-term growth prospects, with many bulls emphasizing its consistent beat-and-raise history as evidence of strong operational execution.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors react to a Q1 earnings beat and a strategic restructuring of its DOE loan alongside updated capacity plans for its Georgia facility. The community is actively debating the company's long-term path to profitability, weighing production scaling and potential dilution concerns against optimism for the R2 model launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Clearmind Medicine Stock Sliding On Wednesday?

Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. Read more on the impact of CMND-100 trial results and new executive orders.read more...

US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results

US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.read more...

<ul class="summary-bullets"><li>Trump also allocated $50 million in federal funding for related research.</li><li>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines.</li><li>Meanwhile, investors are also tracking Silo Pharma, which is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder.</li></ul>Shares of Clearmind Medicines (CMND) surged nearly 65% in pre-market trading on Monday, putting the stock on track for its biggest intraday gain since August 2022, after U.S. President Donald Trump signed an executive order to accelerate access to psychedelic-based treatments.Separately, Clearmind Medicine, on Monday, said its drug CMND-100 met the main goal in an early-stage trial for Alcohol Use Disorder. The treatment showed strong safety, with no serious side effects reported, even at higher doses.<h2 class="st-heading-2">$50M PTSD Boost</h2>On Saturday, Trump signed an executive order to accelerate research and access to psychedelic-based therapies, bringing renewed attention to treatments for post-traumatic stress disorder (PTSD). The order directs the U.S. Food and Drug Administration to fast-track the review of drugs such as Ibogaine, while allocating $50 million in federal funding for related research.Ibogaine, derived from a Central and West African shrub, remains a Schedule I substance in the U.S., though interest is rising among veteran groups exploring its therapeutic potential. Officials say the move could pave the way for reclassification if clinical trials prove successful, with decisions potentially coming as early as this summer.<h2 class="st-heading-2">All Eyes On Clearmind’s Ibogaine Combination Therapy</h2>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines, a type of fatty acid amide. The patent builds on Clearmind’s collaboration with SciSparc, in which both companies are developing combination therapies pairing psychedelic compounds with molecules such as Palmitoylethanolamide to improve treatment outcomes.Ibogaine has shown promise in clinical studies for treating opioid, cocaine, and other substance use disorders, making it a potential anti-addiction therapy.<a href="https://stocktwits.com/symbol/SILO">SILO stock</a> was down 3% at the time of writing.<h2 class="st-heading-2">Silo’s SPC-15 Development Gets A Boost</h2>Meanwhile, Silo Pharma (SILO) also generated a strong buzz after Trump’s order. The firm is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder. The treatment uses a fast nose-to-brain delivery approach. It is being developed under a faster regulatory pathway, the firm added.“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions. We believe Silo is well positioned with SPC-15 and its broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment,” said Eric Weisblum, CEO of Silo Pharma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CMND">CMND</a> on Stocktwits turned ‘extremely bullish, while sentiment for SILO was ‘bullish.’ Message volumes for CMND were ‘extremely high,’ a whopping 535% increase over the past 24 hours, according to Stocktwits data.One user tracking CMND saw the $1.35-$1.37 level as key resistance.<stembedurl>https://stocktwits.com/minimalistreview/message/650748815</stembedurl>Another user highlighted CMND’s “good results,” adding that the stock could climb over $2.<stembedurl>https://stocktwits.com/Maik237/message/650748439</stembedurl>Year-to-date, CMND shares have declined by more than 66%, while SILO stock has climbed by around 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump speaks during a news conference in James S. Brady Press Briefing Room of the White House on April 06, 2026 in Washington, DC. (Photo by Alex Wong/Getty Images)

CMND Stock Set For Biggest Intraday Gains In Over Three Years  — Here’s Why Retail Is Eyeing Further Upside

Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.

Equity

<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment...

Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders

(RTTNews) - Clearmind Medicine (CMND) announced that it has entered into a development agreement with Polyrizon to create a proprietary intranasal formulation of MEAI, a non-hallucinogenic...

Why Did Clearmind Medicine Shares Plunge 29% After Hours?

Clearmind Medicine shares dropped in after-hours trading following the company's announcement of a 1-for-40 reverse stock split.read more...

Penny Stocks To Add to Your Watchlist - November 13th

Leap Therapeutics, Nuvve, Bitfarms, Safe & Green, TNL Mediagene, Strive, and Clearmind Medicine are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks...

Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On?

Clearmind Medicine Inc (NASDAQ:CMND) shares are trading higher on Thursday. Here's a look at what you need to know.read more...

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Current Price	$0.7124
Prev Close	$0.696
Open	$0.7099
Dividend Yield	0.00%
50-Day Moving Average	$0.9594
Beta	0.32
Avg. Volume	182,824.18
PE Ratio	-0.03

52-Week High	$52.40
52-Week Low	$0.5855
Market Capitalization	$1.45M
EPS (Annual)	-$30.35
Price to Book	0.13
Revenue Per Employee	N/A

CMND
Clearmind Medicine Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CMND News

CMNDClearmind Medicine Inc